Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sabinsa adds Canadian patent

This article was originally published in The Tan Sheet

Executive Summary

The Piscataway, N.J.-based dietary supplement manufacturer on Aug. 6 says it has added a patent from Canada to its U.S., European and Japanese patents protecting its Bioperine branded ingredient, which is derived from piperine black pepper extract, for use as a bioavailability enhancer. The firm says Bioperine is the only piperine that can legally be used in Canada to enhance the bioavailability of nutrients in supplement products. Sabinsa retained exclusive U.S. proprietary rights to its BioPerine and Forslean (coleus forkskohlii) ingredients in June with a final judgment by the U.S. District Court for the District of New Jersey against DNP International, which Sabinsa sued for patent infringement because it marketed and distributed piperine and coleus for uses previously researched and patented by Sabinsa in the late 1960s (1"The Tan Sheet" July 9, 2007, In Brief)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS100805

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel